Lopinavir/ritonavir treatment in HIV antiretroviral‐experienced patients: evaluation of risk factors for liver enzyme elevationPaola Meraviglia, A. Cargnel, Monica Schiavini et al.|HIV Medicine|2004Cited by 61
Neutrophil Count and Ambulatory Pulse Pressure as Predictors of Cardiovascular Adverse Events in Postmenopausal Women with HypertensionFabio Angeli, Paolo Verdecchia, Elena Angeli et al.|American Journal of Hypertension|2011Cited by 32
755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICSPietro Lampertico, M. Colombo, R. Soffredini et al.|Journal of Hepatology|2013Cited by 24
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosisPietro Lampertico, M. Colombo, Elena Angeli et al.|Digestive and Liver Disease|2014Cited by 23
Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients.Monica Schiavini, G. Gubertini, Elena Angeli et al.|PubMed|2011Cited by 18